Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28756536 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL10711825 | 0.83 | RAB9A (0.70) | SMN1; SMN2LMNAALDH1A1HPGDALOX12 | |
| SCHEMBL2005846 | 0.83 | RAB9A (0.73) | SMN1; SMN2HSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL29528561 | 0.83 | RAB9A (0.73) | SMN1; SMN2HSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL27144018 | 0.82 | TSHR (0.70) | TSHRKDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL14818749 | 0.81 | TSHR (0.68) | TSHRKDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL31656350 | 0.81 | TSHR (0.68) | SMN1; SMN2TSHRKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL19388071 | 0.81 | POLB (0.68) | SMN1; SMN2TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL11718177 | 0.81 | TSHR (0.68) | TSHRKDM4EHSD17B10GAAHPGD | |
| SCHEMBL28089629 | 0.81 | TSHR (0.68) | TSHRKDM4EHSD17B10LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326103-A1 | CARBOCYCLIC SULFONE ROR GAMMA MODULATORS | BRISTROL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | US | disclosed |
| US-8968973-B2 | Color filter and production method thereof, and solid-state image sensor using the same | FUJIFILM CORPORATION (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8968973-B2 | Color filter and production method thereof, and solid-state image sensor using the same | FUJIFILM CORPORATION (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20100040963-A1 | COLOR FILTER AND PRODUCTION METHOD THEREOF, AND SOLID-STATE IMAGE SENSOR USING THE SAME | FUJIFILM CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | SMN1; SMN2 3638/4885TSHR 430/4885KDM4E 1350/4885 |
| US-20160326103-A1 | CARBOCYCLIC SULFONE ROR GAMMA MODULATORS | RORC, RORB, RORA | SMN1; SMN2 1917/4885TSHR 370/4885KDM4E 2720/4885 |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, CYP1A2, COQ8A | SMN1; SMN2 1192/4885TSHR 1806/4885KDM4E 3756/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | SMN1; SMN2 3638/4885TSHR 430/4885KDM4E 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.